Dublin, Aug. 12, 2024 (GLOBE NEWSWIRE) — The “Gastrointestinal Agents Market by Type (Dietary Supplements, Drugs), Disease Type (Constipation, Diarrhea, Gastroesophageal Reflux Disease), Route of Administration, Distribution Channel, End-User – Forecast 2024-2030” report has been added to ResearchAndMarkets.com’s offering.
The Gastrointestinal Agents Market grew from USD 57.26 billion in 2023 to USD 60.06 billion in 2024. It is expected to continue growing at a CAGR of 4.97%, reaching USD 80.47 billion by 2030.
The rise in gastrointestinal diseases around the world, including conditions such as gastroesophageal reflux disease, peptic ulcers, and inflammatory bowel disease (IBD), drives the need for effective gastrointestinal agents. Growing awareness about gastrointestinal health and improved access to healthcare services in developing regions also contribute to the expanded use of GI agents.
High treatment costs and drug resistance issues with gastrointestinal agents hamper the market growth. Ongoing research and development in gastroenterology led to introduction of more effective and safer drugs, which are expected to create opportunities for gastrointestinal agent market.
Regional Insights
In the Americas, the gastrointestinal agents market is highly developing due to advanced healthcare systems, high awareness of gastrointestinal disorders, and substantial investments in healthcare. The higher prevalence of gastrointestinal diseases and the strong presence of pharmaceutical companies create a platform for the gastrointestinal agents market. In South America, improvements in healthcare infrastructure and increased health insurance coverage are gradually boosting the market.
The APAC region is seeing rapid growth in the gastrointestinal agents market driven by increasing population, rising healthcare expenditures, and growing awareness of gastrointestinal disorders. Countries such as Japan, China, and India are leading this growth due to their large populations and increasing middle class, which has better access to healthcare services. Additionally, Asia-Pacific is experiencing a shift towards Western diets, increasing the prevalence of gastrointestinal issues.
Europe is a major region in the global gastrointestinal agents market, with advanced healthcare systems and a high prevalence of gastrointestinal diseases. Regulatory support and the presence of major pharmaceutical companies also contribute to the growth of this market.
The Gulf Cooperation Council (GCC) countries show higher market penetration due to better healthcare infrastructure, while other parts of Africa are emergent markets with limited access to healthcare.
Market Insights
Market Drivers
Growing prevalence of gastrointestinal disorders across the globe
Educational campaigns about gastrointestinal health and available treatments
Favorable changes in health insurance coverage and reimbursement policies
Market Restraints
Market Opportunities
Market Challenges
Market Segmentation Analysis
Type: Growing usage of dietary supplements with an increasing number of health-conscious consumers
End-User: High potential of gastrointestinal agents across hospitals & clinics as part of initial treatment and ongoing management plans for patients
Recent Developments
Introduction of Calm & Focus: A Zembrin and GABA-Based Dietary Supplement by PLT Health Solutions
PLT Health Solutions, in collaboration with Now, has launched ‘Calm & Focus with Zembrin & GABA’, a new dietary supplement formulated for cognitive enhancement. This product incorporates Zembrin, a patented extract of the South African plant Sceletium tortuosum, traditionally used by the Khoi-San people for mood enhancement and stress reduction. The supplement is designed to offer rapid benefits, promoting alertness, serene focus, and improved mental functionality through the combined effects of Zembrin and GABA, ensuring a balanced approach to stress management and cognitive support.
Innovative Women’s Health Probiotics Launched by Designs for Health
Designs for Health has introduced two new products tailored for women’s health across different life stages. The first, ProbioMed Women, is a daily probiotic supplement containing 25 billion CFUs from 10 clinically researched strains. This formulation is engineered to support vaginal pH, microflora balance in the vagina, and gastrointestinal microbial equilibrium.
Market Introduction of Wonderbelly Antacid with Exclusive Flavor at Target Stores
Wonderbelly, an Austin, Texas-based company, is launching its FDA-regulated Wonderbelly Antacid in select Target stores, featuring a Target-exclusive flavor, Fruity Cereal. The product line, designed to alleviate heartburn, acid indigestion, and sour stomach, includes Strawberry Milkshake and Watermelon Mint flavors. This introduction aims to attract customers seeking effective over-the-counter digestive solutions with appealing flavor options.
Key Attributes:
Report Attribute
Details
No. of Pages
195
Forecast Period
2024 – 2030
Estimated Market Value (USD) in 2024
$60.06 Billion
Forecasted Market Value (USD) by 2030
$80.47 Billion
Compound Annual Growth Rate
4.9%
Regions Covered
Global
Companies Profiled:
Abbott Laboratories
American Health
Amway
Archer-Daniels-Midland
ARKOPHARMA Laboratories
Bayer
Biomedical Research Laboratories
DuPont de Nemours
Dymatize Enterprises
FANCL
Glanbia
GlaxoSmithKline
Herbalife Nutrition
Himalaya Wellness Company
Nature’s Sunshine Products
Nestle
Nutraceutical International
NutraScience Labs
Otsuka Holdings
Pfizer
Pragati Biocare
Procter & Gamble Health
Pure Encapsulations
Sabinsa
Sanofi
Key Topics Covered:
1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights 5.1. Market Dynamics 5.2. Market Segmentation Analysis 5.2.1. Type: Growing usage of dietary supplements with an increasing number of health-conscious consumers 5.2.2. End-User: High potential of gastrointestinal agents across hospitals & clinics as part of initial treatment and ongoing management plans for patients 5.3. Market Disruption Analysis 5.4. Porter’s Five Forces Analysis 5.5. Value Chain & Critical Path Analysis 5.6. Pricing Analysis 5.7. Technology Analysis 5.8. Patent Analysis 5.9. Trade Analysis 5.10. Regulatory Framework Analysis
6. Gastrointestinal Agents Market, by Type 6.1. Introduction 6.2. Dietary Supplements 6.3. Drugs
13. Europe, Middle East & Africa Gastrointestinal Agents Market
14. Competitive Landscape 14.1. Market Share Analysis, 2023 14.2. FPNV Positioning Matrix, 2023 14.3. Competitive Scenario Analysis 14.3.1. Introduction of Calm & Focus: A Zembrin and GABA-Based Dietary Supplement by PLT Health Solutions 14.3.2. Innovative Women’s Health Probiotics Launched by Designs for Health 14.3.3. Market Introduction of Wonderbelly Antacid with Exclusive Flavor at Target Stores 14.4. Strategy Analysis & Recommendation
About ResearchAndMarkets.com ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
More Stories
Cylinder Recognized Nationally for Digestive Health
Study reveals high carbon footprint of gastrointestinal endoscopy, urges sustainable healthcare practices
Global Gastrointestinal Endoscopy Devices Market Size, Share, Trends, Forecast 2025-2034 – Custom Market Insights